How will technology impact medical practice?

Original research by M3 Global Research was featured in City AM and Business Reporter this week. Our findings on how physicians think technology will impact medical practice was included in Anna Delaney’s article ‘What healthtech can learn from fintech’.

With healthcare being touted as one of the tech trends to watch over 2018, the text is built on the idea that technology in healthcare might soon have the same impact it has had in consumer’s banking behaviour.

Delaney highlights that, according to the survey conducted by M3 Global Research earlier this year, 26% of UK doctors see that investment in self-diagnosis technology will have the most impact on patients over the next five years. And she goes on to ask: will this make people increasingly independent from their doctors?

The article doesn’t fail to mention the importance of developing trust, and suggests that having trained and accredited physicians involved is key.

Click here to read the full text.

Researchers Develop Test That Can Diagnose Two Cancer Types

This is an article published by the Georgia State University.

Melanoma_(7)

A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Researchers used mid-infrared spectroscopy to analyze blood serum derived from experimental mice and differentiate mice with non-Hodgkin’s lymphoma and subcutaneous melanoma from healthy mice and also between these two tumorous conditions. The mid-infrared spectral region of the electromagnetic spectrum is frequently used to characterize biological samples at the molecular level.

The findings, published in the journal Scientific Reports, suggest infrared spectroscopy can detect biochemical changes induced by non-Hodgkin’s lymphoma, a solid tumorous condition of the immune system, and subcutaneous melanoma, a deadly form of skin cancer, and has diagnostic potential as a screening technique for these cancers.

Studies have found the incidence rates of cutaneous melanoma have increased in many regions and populations over the last decade, specifically 3 to 7 percent per year among fair-skinned populations. Also, non-Hodgkin’s lymphoma accounts for 4.3 percent of new cancer cases in the United States. The available diagnostic regimen for both cancers, which includes tissue examination and biopsy, is time-consuming, invasive and costly, resulting in small compliance rates of eligible populations for cancer prescreening.

Developing a rapid and reliable prescreening strategy for melanoma and lymphoma is critical because early diagnosis and treatment of these malignancies improve the patients’ chances of survival. Fourier Transform Infrared (FTIR) spectroscopy in Attenuated Total Reflection (ATR) sampling mode provides high-quality results with better reproducibility compared to other vibrational spectroscopy. It has attracted scientists’ attention for its rapid and reliable detection of various health conditions using body fluid samples.

In previous work, Dr. Unil Perera, Regents’ Professor of Physics at Georgia State, and his colleagues discovered that a fast, simple blood test for ulcerative colitis using ATR-FTIR spectroscopy could provide a cheaper, less invasive alternative for screening compared to colonoscopy.

“Our final goal is to say we can use this infrared technique to identify various diseases,” Perera said. “This study shows infrared spectroscopy can identify cancer. Right now, when you go to the doctor, they do blood tests for sugar and several other things, but not for serious diseases like cancer and colitis. If you are a healthy person, there is a range that is normal. One day, we hope that even these serious diseases can be rapidly screened. Your primary doctor could keep a record of your number and check that every time you come back. Then, if there is some indication of cancer or colitis, they can do biopsies, colonoscopies, etc.”

In this recent study, the researchers used mice with lymphoma and melanoma cancers. Blood serum droplets extracted from cancerous mice and control mice were placed on an ATR crystal of the FTIR instrument. Incident infrared beams were absorbed and reflected by the serum, creating a wave that was recorded and used to produce an absorbance curve with peaks that identified the presence of certain biomarkers in the sample.

The researchers compared the absorbance curves from the control and tumorous mice and assessed biochemical changes induced by non-Hodgkin’s lymphoma and subcutaneous melanoma in the serum samples obtained from Dr. Yuan Liu’s research lab in Georgia State’s Department of Biology.

The study found remarkable differences between the ATR-FTIR spectra of serum samples from tumor-bearing mice with melanoma and non-Hodgkin’s lymphoma and healthy, control mice.

The findings are applicable to humans because mice and humans have some biomarkers and chemicals in common, Perera said. In previous studies on colitis, Perera and his colleagues identified specific chemicals that changed in humans and mice when colitis was present.

Using the data collected on the biomarkers for lymphoma and melanoma, the researchers can develop detectors for these particular absorbance peaks, which doctors could use to test patients’ blood samples for these cancers.

Doctors could track a patient’s blood test numbers starting in infancy and monitor them over the years to know exactly when the numbers begin to change. To make before and after comparisons of the blood samples, the data could be entered into a computer program and available statistical analysis software would determine any significant differences. Doctors wouldn’t need to do any sophisticated analysis, Perera said.

This work could lay the foundation for further research that could lead to the development of diagnostic techniques for the health care of melanoma and lymphoma cancer patients using body fluid samples that can be collected with relatively low risks, Perera said. In the future, Perera and his colleagues would like to use samples from human patients for infrared spectroscopy studies of cancer and other diseases.

Other authors of the study include Hemendra Ghimire, a Ph.D. student in the Department of Physics and Astronomy at Georgia State, and Mahathi Venkataramani, Dr. Zhen Bian and Dr. Yuan Liu of the Department of Biology at Georgia State.

The study is funded by the U.S. Army Research Office, the Air Force Office of Scientific Research and the National Institutes of Health.

 

All rights belong to the Georgia State UniversityFeatured Researcher: Dr. Unil Perera. We would like to thank the Georgia State University for sharing this content with us.

Join M3 Global Research at ESMO and ERS

September will be a very busy month for M3 Global Research! We will be attending two large European medical congresses where we will be spreading the word about our paid studies and the work we do towards improving health and patient care.

Please save the date and pop by our stand to learn more about us. If you are already part of the M3 Global Research community, we invite you to bring colleagues to join us. We have some fun and exciting giveaways!

ESMO 2017 Congress

 ESMO

From the 8th to 12th of September we will be in Madrid for the ESMO 2017 Congress. The annual meeting for oncology professionals in Europe, in partnership with the European Association for Cancer Research, promises to provide important clinical updates where researchers and clinicians can exchange knowledge and ideas with the final goal of improving the lives of cancer patients. Come find us at STAND 214, hall 7.

For more information please access: http://www.esmo.org/Conferences/ESMO-2017-Congress/

ERS International Congress

ERS

From the 9th to 13th of September we will be in Milan for the ERS International Congress. This is the largest respiratory meeting in the world, with an outstanding scientific and educational programme that addresses researchers, clinicians, general practitioners and health professionals.

Come find us at STAND R.10. For more information please access: https://erscongress.org/

Looking forward to meeting you either in Madrid or Milan!

The M3 Global Research Team.

Haematologists needed – ‘Real World’ study on Haemophilia

This month we are very pleased to present a special study on Haemophilia. This study will be using a methodology known as ‘Real World’. This methodology is becoming increasingly important as it provides a truly in-depth analysis of the chosen subject matter by involving both the treaters and those receiving the treatment. This in turn allows us to gain a better understanding of the needs and challenges encountered by the physicians and patients alike.

We are looking for haematologists who treat this disorder in UK, US, France, Germany, Italy and Spain.

The total incentive of this study will be up to £1000/$1000/1000€.

Would you like to participate?

Register today

These are some of the benefits of this particular type of studies that respondents will benefit from:

  • High profile haemophilia Patient Outcome
  • Results will be used to ensure the best possible treatment guidelines
  • The results will be published in peer-review journals and presented at key conferences 
  • Your opinions and insights will directly lead to improvement in patients treatments and quality of life
  • Pharmaceutical companies increase focus on patients and regulators look towards real world patient outcomes to support decisions

Phases of the study:

Haematologist needed

Please click here to have further information about this study.

united-states (3) REAL WORLD_Patient Outcome Survey

italy (1) REAL WORLD_Patient Outcome Survey

spain (2) REAL WORLD_Patient Outcome Survey

germany (2) REAL WORLD_Patient Outcome Survey

france (1) REAL WORLD_Patient Outcome Survey

Click on the following links to visualise previous papers published in medical journals from other Real World studies:

“Quality of Life of Patients With Alzheimer’s Disease” presented at ISPOR 19th Annual European Congress (2016)

“Patient-reported Symptom Burden Among Relapsing-Remitting Multiple Sclerosis (RRMS) vs Secondary Progressive Multiple Sclerosis Patients (SPMS) in Europe” presented at 1st Congress of the European Academy of Neurology

We invite you to register today and participate in this study. Your participation will directly lead to improvement in patients treatments.

The M3 Global Research Team